<?xml version="1.0" encoding="UTF-8"?>
<ref id="B119">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Leo</surname>
    <given-names>Y. S.</given-names>
   </name>
   <name>
    <surname>Wilder-Smith</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Archuleta</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Shek</surname>
    <given-names>L. P.</given-names>
   </name>
   <name>
    <surname>Chong</surname>
    <given-names>C. Y.</given-names>
   </name>
   <name>
    <surname>Leong</surname>
    <given-names>H. N.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2012</year>). 
  <article-title>Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years: phase II randomized controlled trial in Singapore</article-title>. 
  <source>Hum. Vaccin. Immunother.</source>
  <volume>8</volume>, 
  <fpage>1259</fpage>–
  <lpage>1271</lpage>. 
  <pub-id pub-id-type="doi">10.4161/hv.21224</pub-id>
  <pub-id pub-id-type="pmid">22894958</pub-id>
 </mixed-citation>
</ref>
